These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 29451965)

  • 41. Pentraxin 3 level is elevated in hereditary hemorrhagic telangiectasia and reflects the severity of disease-associated epistaxis.
    Steineger J; Ueland T; Aukrust P; Michelsen A; Osnes T; Heimdal K; Dheyauldeen S
    Laryngoscope; 2019 Jan; 129(1):E44-E49. PubMed ID: 30329172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial.
    Yaniv E; Preis M; Shevro J; Nageris B; Hadar T
    Rhinology; 2011 Jun; 49(2):214-6. PubMed ID: 21743879
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia].
    Rohrmeier C; Kühnel TS
    HNO; 2012 Nov; 60(11):1003-6. PubMed ID: 22706563
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia.
    Thompson KP; Sykes J; Chandakkar P; Marambaud P; Vozoris NT; Marchuk DA; Faughnan ME
    Orphanet J Rare Dis; 2022 Nov; 17(1):405. PubMed ID: 36344987
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report.
    Ospina FE; Echeverri A; Posso-Osorio I; Jaimes L; Gutierrez J; Tobón GJ
    Colomb Med (Cali); 2017 Jun; 48(2):88-93. PubMed ID: 29021642
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients.
    Pagella F; Colombo A; Matti E; Giourgos G; Tinelli C; Olivieri C; Danesino C
    Am J Rhinol Allergy; 2009; 23(1):52-8. PubMed ID: 19379613
    [TBL] [Abstract][Full Text] [Related]  

  • 47. European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?
    Dupuis-Girod S; Shovlin CL; Kjeldsen AD; Mager HJ; Sabba C; Droege F; Fargeton AE; Fialla AD; Gandolfi S; Hermann R; Lenato GM; Manfredi G; Post MC; Rennie C; Suppressa P; Sure U; ; Buscarini E
    Eur J Med Genet; 2022 Oct; 65(10):104575. PubMed ID: 35940549
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
    Karnezis TT; Davidson TM
    Laryngoscope; 2011 Mar; 121(3):636-8. PubMed ID: 21344445
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia.
    Kanellopoulou T; Alexopoulou A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1315-23. PubMed ID: 23815519
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.
    Rohrmeier C; Sachs HG; Kuehnel TS
    Eur Arch Otorhinolaryngol; 2012 Feb; 269(2):531-6. PubMed ID: 21805356
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intranasal Efudix reduces epistaxis in hereditary hemorrhagic telangiectasia.
    de Jel DVC; Disch FJM; Kroon S; Mager JJ; Verdam FJ
    Angiogenesis; 2020 Aug; 23(3):271-274. PubMed ID: 32112177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial.
    Peterson AM; Lee JJ; Kallogjeri D; Schneider JS; Chakinala MM; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1006-1014. PubMed ID: 32940653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia.
    Al-Samkari H; Kasthuri RS; Iyer VN; Pishko AM; Decker JE; Weiss CR; Whitehead KJ; Conrad MB; Zumberg MS; Zhou JY; Parambil J; Marsh D; Clancy M; Bradley L; Wisniewski L; Carper BA; Thomas SM; McCrae KR
    N Engl J Med; 2024 Sep; 391(11):1015-1027. PubMed ID: 39292928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies.
    Kaja S; Hilgenberg JD; Everett E; Olitsky SE; Gossage J; Koulen P
    Hum Antibodies; 2011; 20(3-4):95-101. PubMed ID: 22129679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plasma VEGF - a candidate biomarker for response to treatment with bevacizumab in HHT patients.
    Liu DT; Frohne A; Koenighofer M; Frei K; Lucas T; Riss D; Parzefall T
    Rhinology; 2020 Feb; 58(1):18-24. PubMed ID: 31681913
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
    Chen S; Karnezis T; Davidson TM
    Laryngoscope; 2011 Mar; 121(3):644-6. PubMed ID: 21344447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hereditary hemorrhagic telangiectasia: a rare cause of severe anemia.
    dos Santos JW; Dalcin TC; Neves KR; Mann KC; Pretto GL; Bertolazi AN
    J Bras Pneumol; 2007; 33(1):109-12. PubMed ID: 17568877
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A lack of race and ethnicity data in the treatment of hereditary hemorrhagic telangiectasia: a systematic review of intravenous bevacizumab efficacy.
    Galiatsatos P; Wilson C; O'Brien J; Gong AJ; Angiolillo D; Johnson J; Myers C; Strout S; Mathai S; Robinson G; Rowan NR; Weiss CR
    Orphanet J Rare Dis; 2022 Jun; 17(1):220. PubMed ID: 35698080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report.
    Steineger J; Merckoll E; Slåstad JM; Eriksen EF; Heimdal K; Dheyauldeen S
    Laryngoscope; 2018 Mar; 128(3):593-596. PubMed ID: 28671294
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study.
    Kroon S; Snijder RJ; Hosman AE; Vorselaars VMM; Disch FJM; Post MC; Mager JJ
    Angiogenesis; 2021 May; 24(2):379-386. PubMed ID: 33211216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.